BILLERICA, Mass., July 31, 2017 /PRNewswire/ — Bruker today announces that it has received US Food & Drug Administration (FDA) clearance for its third, further expanded claim for the market-leading MALDI Biotyper-CA (MBT-CA) system for fast, accurate and cost-effective microbial identification. The new claim includes a significant expansion of the microbial reference library for clinical... Read more
Basel, 28 July 2017 FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia First in class BCL2-specific oral inhibitor represents a potential new way of treating acute myeloid leukaemia (AML), the most common type of aggressive leukaemia in adults1 17th breakthrough therapy designation for Roche’s portfolio of medicines and 4th for Venclexta Roche... Read more
Collaboration aims to strengthen training opportunities in the latest technologies for young researchers IPSWICH, Mass. and HEIDELBERG, Germany, July 25, 2017 /PRNewswire/ — The EMBL Advanced Training Centre (ATC) welcomes New England Biolabs (NEB®) as its newest member of their Corporate Partnership Programme. Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life... Read more
AUSTIN, Texas, July 24, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES®C. difficile Assay, a moderate complexity, sample to answer test for rapid detection of C. difficile. The ARIES®C. difficile Assay detects both toxin A and toxin B, which may reduce the probability of a false... Read more
AUSTIN, Texas, July 24, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES®C. difficile Assay, a moderate complexity, sample to answer test for rapid detection of C. difficile. The ARIES®C. difficile Assay detects both toxin A and toxin B, which may reduce the probability of a false... Read more
Download PDF Read more
FRANKLIN LAKES, N.J., July 19, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest™ assays... Read more
Partnership will further develop Kailos’ leading-edge next-generation sequencing solutions for the intelligence community July 11, 2017 09:00 AM Eastern Daylight Time HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced a strategic partnership with and investment from In-Q-Tel, Inc. (IQT). IQT is the... Read more
MELVILLE, N.Y., July 10, 2017 (GLOBE NEWSWIRE) — Nikon Instruments Inc. is pleased to announce development of the newest Nikon Imaging Center is underway at the University of California San Diego (UC San Diego). This collaborative microscopy center provides researchers from UC San Diego and the local research community with access to the latest generation... Read more
Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan* Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan... Read more